• Je něco špatně v tomto záznamu ?

Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods

J. Janockova, R. Dolezal, E. Nepovimova, T. Kobrlova, M. Benkova, K. Kuca, J. Konecny, E. Mezeiova, M. Melikova, V. Hepnarova, A. Ring, O. Soukup, J. Korabecny,

. 2018 ; 23 (11) : . [pub] 20181109

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012158

The neuropeptides, orexin A and orexin B (also known as hypocretins), are produced in hypothalamic neurons and belong to ligands for orphan G protein-coupled receptors. Generally, the primary role of orexins is to act as excitatory neurotransmitters and regulate the sleep process. Lack of orexins may lead to sleep disorder narcolepsy in mice, dogs, and humans. Narcolepsy is a neurological disorder of alertness characterized by a decrease of ability to manage sleep-wake cycles, excessive daytime sleepiness, and other symptoms, such as cataplexy, vivid hallucinations, and paralysis. Thus, the discovery of orexin receptors, modulators, and their causal implication in narcolepsy is the most important advance in sleep-research. The presented work is focused on the evaluation of compounds L1−L11 selected by structure-based virtual screening for their ability to modulate orexin receptor type 2 (OX2R) in comparison with standard agonist orexin-A together with their blood-brain barrier permeability and cytotoxicity. We can conclude that the studied compounds possess an affinity towards the OX2R. However, the compounds do not have intrinsic activity and act as the antagonists of this receptor. It was shown that L4 was the most potent antagonistic ligand to orexin A and displayed an IC50 of 2.2 μM, offering some promise mainly for the treatment of insomnia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012158
003      
CZ-PrNML
005      
20221026130014.0
007      
ta
008      
190405s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules23112926 $2 doi
035    __
$a (PubMed)30423961
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Janockova, Jana $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. jana.janockova@fnhk.cz. Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. jana.janockova@fnhk.cz.
245    10
$a Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods / $c J. Janockova, R. Dolezal, E. Nepovimova, T. Kobrlova, M. Benkova, K. Kuca, J. Konecny, E. Mezeiova, M. Melikova, V. Hepnarova, A. Ring, O. Soukup, J. Korabecny,
520    9_
$a The neuropeptides, orexin A and orexin B (also known as hypocretins), are produced in hypothalamic neurons and belong to ligands for orphan G protein-coupled receptors. Generally, the primary role of orexins is to act as excitatory neurotransmitters and regulate the sleep process. Lack of orexins may lead to sleep disorder narcolepsy in mice, dogs, and humans. Narcolepsy is a neurological disorder of alertness characterized by a decrease of ability to manage sleep-wake cycles, excessive daytime sleepiness, and other symptoms, such as cataplexy, vivid hallucinations, and paralysis. Thus, the discovery of orexin receptors, modulators, and their causal implication in narcolepsy is the most important advance in sleep-research. The presented work is focused on the evaluation of compounds L1−L11 selected by structure-based virtual screening for their ability to modulate orexin receptor type 2 (OX2R) in comparison with standard agonist orexin-A together with their blood-brain barrier permeability and cytotoxicity. We can conclude that the studied compounds possess an affinity towards the OX2R. However, the compounds do not have intrinsic activity and act as the antagonists of this receptor. It was shown that L4 was the most potent antagonistic ligand to orexin A and displayed an IC50 of 2.2 μM, offering some promise mainly for the treatment of insomnia.
650    _2
$a zvířata $7 D000818
650    _2
$a vazebná místa $7 D001665
650    _2
$a CHO buňky $7 D016466
650    12
$a počítačová simulace $7 D003198
650    _2
$a Cricetulus $7 D003412
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a ligandy $7 D008024
650    12
$a molekulární modely $7 D008958
650    _2
$a molekulární konformace $7 D008968
650    _2
$a molekulární struktura $7 D015394
650    _2
$a antagonisté orexinových receptorů $x chemie $x farmakologie $7 D000068796
650    _2
$a orexinové receptory $x chemie $7 D064446
650    _2
$a orexiny $x chemie $x farmakologie $7 D000068797
650    _2
$a vazba proteinů $7 D011485
650    _2
$a kvantitativní vztahy mezi strukturou a aktivitou $7 D021281
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dolezal, Rafael $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Rafael.dolezal@fnhk.cz. Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. Rafael.dolezal@fnhk.cz. Center for Basic and Applied Research, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. Rafael.dolezal@fnhk.cz.
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. eugenie.nepovimova@uhk.cz.
700    1_
$a Kobrlová, Tereza, $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. tereza.kobrlova@fnhk.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 05 Hradec Kralove, Czech Republic. tereza.kobrlova@fnhk.cz. $d 1991- $7 xx0277928
700    1_
$a Benkova, Marketa $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. marketa.benkova@fnhk.cz.
700    1_
$a Kuca, Kamil $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. kamil.kuca@fnhk.cz. Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. kamil.kuca@fnhk.cz.
700    1_
$a Konecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. jan.konecny@fnhk.cz. Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. jan.konecny@fnhk.cz.
700    1_
$a Mezeiová, Eva $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. eva.mezeiova@fnhk.cz. $7 xx0277560
700    1_
$a Melikova, Michaela $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. michaela.melikova@upol.cz.
700    1_
$a Hepnarova, Vendula $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. vendula.hepnarova@unob.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 05 Hradec Kralove, Czech Republic. vendula.hepnarova@unob.cz.
700    1_
$a Ring, Avi $u Norwegian Defence Research Establishment, Gunnar Randersvei 42, 2007 Kjeller, Norway. avi.ring@ffi.no.
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. ondrej.soukup@fnhk.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 05 Hradec Kralove, Czech Republic. ondrej.soukup@fnhk.cz.
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. jan.korabecny@fnhk.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 05 Hradec Kralove, Czech Republic. jan.korabecny@fnhk.cz.
773    0_
$w MED00180394 $t Molecules $x 1420-3049 $g Roč. 23, č. 11 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30423961 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20221026130011 $b ABA008
999    __
$a ok $b bmc $g 1391468 $s 1050463
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 23 $c 11 $e 20181109 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...